Narcolepsy: Clinical features, co-morbidities & treatment

被引:0
|
作者
Peacock, Jeremy [1 ]
Benca, Ruth M. [1 ]
机构
[1] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA
关键词
Cataplexy; excessive daytime sleepiness; hypocretin; MSLT; narcolepsy; EXCESSIVE DAYTIME SLEEPINESS; ONSET REM PERIODS; QUALITY-OF-LIFE; GAMMA-HYDROXYBUTYRATE; HLA DQB1-ASTERISK-0602; CEREBROSPINAL-FLUID; PRACTICE PARAMETERS; AMERICAN-ACADEMY; CATAPLEXY; MODAFINIL;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Narcolepsy is a neurologic illness that typically begins in the second and third decades of life. It is chronic in nature and negatively impacts the quality of life of affected patients. The classic presentation is a tetrad of excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations. The exact cause remains unknown, but there is significant evidence that hypocretin deficiency plays an integral role. Some primary conditions that result in secondary narcolepsy include traumatic brain injury, congenital disorders, tumours, and strokes. Some medical and psychiatric disorders share characteristics of narcolepsy, at times leading to diagnostic inaccuracy. Other sleep disorders are commonly co-morbid. Diagnosis relies on patient history and objective data gathered from polysomnography and multiple sleep latency testing. Treatment focuses on symptom relief through medication, education, and behavioural modification. Both classic pharmacological treatments as well as newer options have significant problems, especially because of side effects and abuse potential. Novel modalities are being examined to expand options for treatment.
引用
收藏
页码:338 / 349
页数:12
相关论文
共 50 条
  • [11] Identification of co-morbidities
    Sander, Ley
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [12] March 2018 at a glance: clinical trials, co-morbidities and treatment of mitral regurgitation
    Metra, Marco
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (03) : 411 - 412
  • [13] GOUT AND ASSOCIATED CO-MORBIDITIES - RELEVANCE TO CLINICAL PRACTICE
    Roddy, Edward
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 17 - 17
  • [14] Co-morbidities in severe asthma: Clinical impact and management
    Porsbjerg, Celeste
    Menzies-Gow, Andrew
    RESPIROLOGY, 2017, 22 (04) : 651 - 661
  • [15] Co-Morbidities In COPD, Clinical Associations And Relations To Outcomes
    MacNee, W.
    Agusti, A.
    Celli, B.
    Calverley, P. M.
    Coxson, H. O.
    Crim, C.
    Edwards, L.
    Lomas, D. A.
    Miller, B.
    Rennard, S.
    Silverman, E. K.
    Tal-Singer, R.
    Wouters, E. F. M.
    Yates, J.
    Vestbo, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [16] Prevalence and Impact of Co-morbidities on Treatment of Breast Cancer
    Tao, M.
    Khalid, N.
    White, J. R.
    Owen, J. B.
    Pierce, L. J.
    Wilson, J. F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S557 - S557
  • [17] Methylphenidate Treatment in Germany - Are Co-Morbidities Taken into Account?
    Lindemann, Christina
    Angela, Kraut
    Ingo, Langner
    Rafael, Mikolajczyk
    Edeltraut, Garbe
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S226 - S226
  • [18] The treatment of co-morbidities in older patients with metastatic cancer
    Josephine Cashman
    Juliet Wright
    Alistair Ring
    Supportive Care in Cancer, 2010, 18 : 651 - 655
  • [19] Prenatal features, associated co-morbidities and clinical course of agenesis of the ductus venosus in the current era
    McBrien, Angela
    Caluseriu, Oana
    Niederhoffer, Karen Y.
    Hornberger, Lisa K.
    PRENATAL DIAGNOSIS, 2021, 41 (01) : 15 - 20
  • [20] Interstitial cystitisCost, treatment and co-morbidities in an employed population
    Eric Q. Wu
    Howard Birnbaum
    Milena Mareva
    Andrew Parece
    Zihong Huang
    David Mallett
    Haya Taitel
    PharmacoEconomics, 2006, 24 (1) : 55 - 65